Summit's ezutromid reduces muscle damage in DMD

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) gained $1.57 (13%) to $13.78 in New York on Thursday after reporting interim 24-week data from the Phase II PhaseOut DMD trial showing that twice-daily ezutromid (SMT C1100) reduced muscle damage in Duchenne muscular dystrophy patients. Summit gained 37.50p (21%) to 215p in London.

Compared to baseline, ezutromid significantly reduced muscle damage at week 24 by 23% as measured by mean developmental myosin. Of 22 evaluable patients, 14 showed a reduction in development myosin, which was greater than 40% in five patients...